Redeye returns following Kancera's Q1 report. The investment case is currently centred around the le...
Hansa Biopharma plans to restructure the organisation to optimise resource allocation and improve op...
Redeye comments on Lipigon’s first quarter report 2025.
Organic sales growth of 13% y-o-y in Q1 Profitability improvement in Security Solutions.
Redeye provides its key insights from the Grassfish Summit and Digital Signage Summit Europe based o...
Redeye provides its preview of Integrum’s Q4 2024 report, due on Tuesday, June 3.
Redeye provides an update following Jumpgate’s Q1 2025 report, where we observed a top line largely ...
Nettoomsättningen i Q1’25 uppgick till 0,1 MSEK (2,0), vilket motsvarade en minskning med 94,5% y.
Q1 revenue was DKK 24m, 22% below ABGSCe Guides for 10.
Seasonally weak quarter, but 2025 guidance firm '25e-'27e adj.
With its third attempt to scale offline payments in India, Crunchfish hopes that its new Offline Ter...
Redeye updates on Better Collective after Q1-results which saw slightly stronger than expected outco...
Redeye shares its thoughts after CTEK’s capital markets day (CMD), which took place on Thursday last...
Redeye comments on Friday evening’s news from Dala Energi’s AGM, where the voluntary share redemptio...
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det första...
ExpreS2ion Biotechnologies har ännu inte startat behandling med sitt vaccin i den fas 1-studie på br...
Q1 revenues 3% below, EBIT DKK -1m vs. ABGSCe DKK 11m FY'25 guidance maintained, as expected Consens...
Redeye comments on Faron’s recent publication in a scientific journal, which provides valuable mecha...
Adj. EBITDA 35% above, but boosted by one-offs in Senior Soft watch sales, but volumes will shift to...
Redeye provides a research update following the Q1 report recently published by Magle.
